U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H33N3O
Molecular Weight 343.5062
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SITAMAQUINE

SMILES

CCN(CC)CCCCCCNC1=C2N=CC=C(C)C2=CC(OC)=C1

InChI

InChIKey=RVAKDGYPIVSYEU-UHFFFAOYSA-N
InChI=1S/C21H33N3O/c1-5-24(6-2)14-10-8-7-9-12-22-20-16-18(25-4)15-19-17(3)11-13-23-21(19)20/h11,13,15-16,22H,5-10,12,14H2,1-4H3

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16945323

Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis. Phase III trials for the treatment of visceral leishmaniasis had been initiated by March 2002, at which time GlaxoSmithKline hoped to file an MAA in 2003. By 1999, the compound had also undergone phase I trials in HIV-infected individuals for the treatment of Pneumocystis carinii infection. Preclinical studies have been conducted in primates and rodents for the potential treatment of Babesia microti infection.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 29.2 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Phase II
1147
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
484.3 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10235511
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SITAMAQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
577 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21633025
2 mg/kg single, oral
dose: 2 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
SITAMAQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
503 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21633025
2 mg/kg 1 times / day multiple, oral
dose: 2 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SITAMAQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
639 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21633025
2 mg/kg 1 times / day single, oral
dose: 2 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
SITAMAQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
451 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21633025
2 mg/kg 1 times / day multiple, oral
dose: 2 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SITAMAQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6916 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10235511
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SITAMAQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7147 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21633025
2 mg/kg single, oral
dose: 2 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
SITAMAQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8350 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21633025
2 mg/kg 1 times / day multiple, oral
dose: 2 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SITAMAQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8574 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21633025
2 mg/kg 1 times / day single, oral
dose: 2 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
SITAMAQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
7723 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21633025
2 mg/kg 1 times / day multiple, oral
dose: 2 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SITAMAQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
18.3 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21633025
2 mg/kg 1 times / day multiple, oral
dose: 2 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SITAMAQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
19.3 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21633025
2 mg/kg 1 times / day multiple, oral
dose: 2 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SITAMAQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
120 mg 1 times / day multiple, oral
MTD
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
DLT: Elevated triglycerides...
Disc. AE: Skin rash, Nausea...
Dose limiting toxicities:
Elevated triglycerides (5.6%)
AEs leading to
discontinuation/dose reduction:
Skin rash (11.1%)
Nausea (5.6%)
Vomiting (5.6%)
Headache (5.6%)
CPK increased (5.6%)
LDH increased (5.6%)
AST increased (5.6%)
ALT increased (5.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
150 mg 1 times / day multiple, oral
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
DLT: Methemoglobinemia, Methemoglobinemia...
Disc. AE: Histoplasmosis, Fever...
Dose limiting toxicities:
Methemoglobinemia (12.5%)
Methemoglobinemia (37.5%)
Elevated triglycerides (12.5%)
AEs leading to
discontinuation/dose reduction:
Histoplasmosis (12.5%)
Fever (12.5%)
Flushing (12.5%)
Skin rash (12.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
2.5 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 2.5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16354802
unhealthy, CHILD,ADULT
Health Status: unhealthy
Age Group: CHILD,ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/16354802
Disc. AE: Cardio-respiratory failure, Bone marrow depression...
AEs leading to
discontinuation/dose reduction:
Cardio-respiratory failure (grade 5, 3.6%)
Bone marrow depression (3.6%)
Bone marrow depression (3.6%)
Nephrotic syndrome (7.2%)
Glomerulonephritis (7.2%)
Acute renal failure (3.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/16354802
AEs

AEs

AESignificanceDosePopulation
Skin rash 11.1%
Disc. AE
120 mg 1 times / day multiple, oral
MTD
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
Elevated triglycerides 5.6%
DLT
120 mg 1 times / day multiple, oral
MTD
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
ALT increased 5.6%
Disc. AE
120 mg 1 times / day multiple, oral
MTD
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
AST increased 5.6%
Disc. AE
120 mg 1 times / day multiple, oral
MTD
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
CPK increased 5.6%
Disc. AE
120 mg 1 times / day multiple, oral
MTD
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
Headache 5.6%
Disc. AE
120 mg 1 times / day multiple, oral
MTD
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
LDH increased 5.6%
Disc. AE
120 mg 1 times / day multiple, oral
MTD
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
Nausea 5.6%
Disc. AE
120 mg 1 times / day multiple, oral
MTD
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
Vomiting 5.6%
Disc. AE
120 mg 1 times / day multiple, oral
MTD
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
Elevated triglycerides 12.5%
DLT
150 mg 1 times / day multiple, oral
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
Methemoglobinemia 12.5%
DLT, Disc. AE
150 mg 1 times / day multiple, oral
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
Fever 12.5%
Disc. AE
150 mg 1 times / day multiple, oral
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
Flushing 12.5%
Disc. AE
150 mg 1 times / day multiple, oral
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
Histoplasmosis 12.5%
Disc. AE
150 mg 1 times / day multiple, oral
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
Skin rash 12.5%
Disc. AE
150 mg 1 times / day multiple, oral
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
Methemoglobinemia 37.5%
DLT
150 mg 1 times / day multiple, oral
Studied dose
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/10235511
Acute renal failure 3.6%
Disc. AE
2.5 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 2.5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16354802
unhealthy, CHILD,ADULT
Health Status: unhealthy
Age Group: CHILD,ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/16354802
Bone marrow depression 3.6%
Disc. AE
2.5 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 2.5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16354802
unhealthy, CHILD,ADULT
Health Status: unhealthy
Age Group: CHILD,ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/16354802
Bone marrow depression 3.6%
Disc. AE
2.5 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 2.5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16354802
unhealthy, CHILD,ADULT
Health Status: unhealthy
Age Group: CHILD,ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/16354802
Glomerulonephritis 7.2%
Disc. AE
2.5 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 2.5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16354802
unhealthy, CHILD,ADULT
Health Status: unhealthy
Age Group: CHILD,ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/16354802
Nephrotic syndrome 7.2%
Disc. AE
2.5 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 2.5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16354802
unhealthy, CHILD,ADULT
Health Status: unhealthy
Age Group: CHILD,ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/16354802
Cardio-respiratory failure grade 5, 3.6%
Disc. AE
2.5 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 2.5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 2.5 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16354802
unhealthy, CHILD,ADULT
Health Status: unhealthy
Age Group: CHILD,ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/16354802
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1741
CYPs
33
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
P-gp
1932
 inconclusive [IC50 23.1093 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYPs
33
 yes
PubMed

PubMed

TitleDatePubMed
Transition metal complexes of quinolino[3,2-b]benzodiazepine and quinolino[3,2-b]benzoxazepine: synthesis, characterization, and antimicrobial studies.
2007
Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
2003-07
Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute).
2002-10
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
1995-11-24
8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models.
1991-02
Patents

Patents

20060172956
2
6316502
2
7927613
119
WO2011033115A2
2

Sample Use Guides

In Vivo Use Guide
oral sitamaquine, 2 mg/kg/day, once a day for 21 days
Route of Administration: Oral
In Vitro Use Guide
Sitamaquine (1 ug/ml) almost completely inhibited P carinii growth in human lung fibroblasts over 10 days. Some inhibition was seen at 0.1 ug/ml, which was a similar level of activity to that of primaquine.
Name Type Language
SITAMAQUINE
INN   MI   WHO-DD  
INN  
Official Name English
WR-6026
Preferred Name English
sitamaquine [INN]
Common Name English
Sitamaquine [WHO-DD]
Common Name English
SITAMAQUINE [MI]
Common Name English
Code System Code Type Description
PUBCHEM
42548
Created by admin on Mon Mar 31 18:28:40 GMT 2025 , Edited by admin on Mon Mar 31 18:28:40 GMT 2025
PRIMARY
INN
7834
Created by admin on Mon Mar 31 18:28:40 GMT 2025 , Edited by admin on Mon Mar 31 18:28:40 GMT 2025
PRIMARY
DRUG BANK
DB04909
Created by admin on Mon Mar 31 18:28:40 GMT 2025 , Edited by admin on Mon Mar 31 18:28:40 GMT 2025
PRIMARY
MERCK INDEX
m9961
Created by admin on Mon Mar 31 18:28:40 GMT 2025 , Edited by admin on Mon Mar 31 18:28:40 GMT 2025
PRIMARY Merck Index
SMS_ID
100000129177
Created by admin on Mon Mar 31 18:28:40 GMT 2025 , Edited by admin on Mon Mar 31 18:28:40 GMT 2025
PRIMARY
EPA CompTox
DTXSID70206395
Created by admin on Mon Mar 31 18:28:40 GMT 2025 , Edited by admin on Mon Mar 31 18:28:40 GMT 2025
PRIMARY
FDA UNII
5AIJ4TGC6B
Created by admin on Mon Mar 31 18:28:40 GMT 2025 , Edited by admin on Mon Mar 31 18:28:40 GMT 2025
PRIMARY
EVMPD
SUB37607
Created by admin on Mon Mar 31 18:28:40 GMT 2025 , Edited by admin on Mon Mar 31 18:28:40 GMT 2025
PRIMARY
CAS
57695-04-2
Created by admin on Mon Mar 31 18:28:40 GMT 2025 , Edited by admin on Mon Mar 31 18:28:40 GMT 2025
PRIMARY
NCI_THESAURUS
C73010
Created by admin on Mon Mar 31 18:28:40 GMT 2025 , Edited by admin on Mon Mar 31 18:28:40 GMT 2025
PRIMARY
ChEMBL
CHEMBL57004
Created by admin on Mon Mar 31 18:28:40 GMT 2025 , Edited by admin on Mon Mar 31 18:28:40 GMT 2025
PRIMARY
MESH
C080436
Created by admin on Mon Mar 31 18:28:40 GMT 2025 , Edited by admin on Mon Mar 31 18:28:40 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of SITAMAQUINE
SALT/SOLVATE (PARENT)
Structure of SITAMAQUINE DIHYDROCHLORIDE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966